Previous 10 | Next 10 |
2023-07-21 10:00:00 ET Up by 32% in the past three months, Caribou Biosciences (NASDAQ: CRBU) is a pre-revenue biotech stock with explosive potential. Per some new data released on July 13, its candidate to treat lymphoma might be a massive winner in the making. But early stage ...
2023-07-17 05:11:51 ET Summary Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/refractory second-line LBCL patients, are expected in the 1st half of 2024. A $25 million equity invest...
2023-07-14 14:12:48 ET Caribou Biosciences is down 23% in Friday trading after announcing following Thursday's closing bell a $125M stock offering and phase 1 data on a non-Hodgkin's lymphoma CAR-T candidate. The offering was upsized to $150M from $125M. It was priced late Thurs...
2023-07-14 10:01:23 ET Gainers: PainReform ( PRFX ) +112% . Acadia Pharmaceuticals ( ACAD ) +15% . Nutriband ( NTRB ) +14% . Arcturus Therapeutics ( ARCT ) +10% . Exicure ( XCUR ) +7% . Losers: Theseus Pharmaceuticals ( ...
2023-07-14 03:31:44 ET Genome-editing biopharmaceutical company Caribou Biosciences ( NASDAQ: CRBU ) has upsized underwritten public offering of 19.23 million shares at a public offering price of $6.50 per share. Gross proceeds from the offering are expected to ...
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 19,230,769 shares of its common stock at a public o...
2023-07-13 16:09:56 ET Genome-editing biopharmaceutical company Caribou Biosciences ( NASDAQ: CRBU ) said on Thursday that it has commenced a $100M underwritten public offering of shares. The company intends to grant the underwriters a 30-day option to purchase up to an a...
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced an underwritten public offering of $100 million of shares of its common stock. Caribou ...
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is th...
2023-07-13 09:30:00 ET The stock market rewards innovation, especially when it comes to new products and/or services that create or disrupt entire industries. Some of the best-performing stocks in the past two decades have been fueled by advances in cutting-edge areas such as artificial int...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...
-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to...